Device Trial Radar · NCT06820606
Comparing Rezum and Urolift
Last checked: Nov 20, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 1, 2025
Primary completion
Sep 30, 2027
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Princess Margaret Hospital, Hong Kong; Pamela Youde Nethersole Eastern Hospital; Alice Ho Miu Ling Nethersole Hospital; North District Hospital
- First posted
- Feb 11, 2025
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- Male only, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized controlled trial using a non-inferiority design with the subjects randomized 1:1 to either water vapour thermal treatment (REZUM) arm or prostatic urethral lift (UroLift) arm.
Conditions
- Benign Prostatic Hyperplasia
Interventions
RezumDevice
In the REZUM arm, water vapour treatment will be preformed.
UroLiftDevice
In the UroLift arm, prostatic urethral lift treatment will be performed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in International Prostate Symptom Score (IPSS) at 12 months after treatmentTime frame: Baseline, 3 months, 6 months and 12 months after intervention
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prince of Wales Hospital, The Chinese University of Hong Kong
Hong Kong, Hong Kong · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.